In pharmaceutical tablet manufacturing processes, a major source of disturbance affecting drug product quality is the (lot to lot) variability of the incoming raw materials. A Feed-Forward process control strategy that compensates for raw material variability is presented. The approach involves building PLS (partial least squares) models that combine raw material attributes and tablet process parameters and relate these to final tablet attributes. The resulting models are used in an optimization framework to then find optimal process parameters which can satisfy all the desired requirements for the final tablet attributes, subject to the incoming raw material lots, prior to performing a batch. The connectivity obtained between the three sources of variability (materials, parameters, attributes) can be considered a design space consistent with Quality by Design (QbD) principles, which is defined by the ICH-Q8 guidance [1] . To implement the FF control, an in-house process simulator is presented. The effectiveness of the methodologies is illustrated through a common industrial tablet manufacturing case study.
INTRODUCTION
The Quality by Design (QbD) concept proposed by the Food and Drug Administration (FDA) plays a significant role in the development process within the pharmaceutical industry [1, 2] . The concept of QbD was mentioned in the ICH Q8 guidance [1] , which states that "quality cannot be tested into products, that is, quality should be built in by design". A key notion is to obtain a design space that is defined as a "multidimensional combination and interaction of input variables (raw material attributes and process parameters) that have been demonstrated to provide assurance of quality" by the ICH-Q8 guidance [1] . This entails definition of (i) the key quality attributes of the finished drug product, (ii) drug product formulation space, that comprises the active pharmaceutical ingredient (API) and pharmacologically inactive components in the formulation, referred to as excipients, that are selected to provide the desired physical and mechanical attributes in the drug product (iii) the manufacturing process / operating parameter space to consistently produce a quality product. MacGregor and Bruwer [3] have provided a framework for the development of design and control spaces that simultaneously considers the raw material characteristic space, process variable space and quality attribute space. This is a key concept to maximize the batch to batch consistency of pharmaceutical drug products. In pharmaceutical manufacturing processes, a major source of disturbance which could affect the drug product quality is the variability of the incoming raw materials. A critical challenge for QbD is how to construct a process control strategy which can compensate for the effect of raw material variability and stabilize drug product quality. This study focuses on a Feed-Forward (FF) control scheme.
With FF control the effect of incoming raw materials can be compensated by suitably adjusting process parameters prior to actually manufacturing a batch. There are two key issues to design FF control: (1) how to build a multivariate model from raw material attributes and process parameters to final tablet attributes; (2) how to find the best process parameters which can compensate for the effect of incoming raw material variability (within constraints of the manufacturing equipment and desired final tablet attributes) prior to manufacturing a batch. Latent Variable Modeling (LVM) methodologies [4] [5] [6] such as Partial Least Squares (PLS) and Principal Component Analysis (PCA) can play a key role to solve the first modeling problem. LVM effectively reduces the large number of original variable dimensions into a lower dimensionality subspace, and provides good estimates for the Y variable(s). In addition, due to the nature of reduction of variable dimensions, LVM allows the building of a good model even with relatively small numbers of drug product batches. For the second problem of FF control design, optimization technologies [7] such as nonlinear programming are deemed to be suitable tools. Muteki et al. [8, 9] provided a novel modeling and process optimization strategy which can de-risk pharmaceutical tablet manufacturing processes while simultaneously taking into account two major disturbances such as scaleup and lot-to-lot variability of the incoming raw materials. However, there have been relatively few published industrial applications of optimization technologies for QbD studies in the pharmaceutical drug product development arena. This paper presents a Feed-Forward process control strategy which can compensate for the effect of raw material (lot-to-lot) variability to achieve desired final tablet attributes in pharmaceutical dosage form
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The International Federation of Automatic Control Furama Riverfront, Singapore, July 10-13, 2012 development (tablet manufactured with a dry granulation process). The approach involves building PLS (partial least squares) models that combine raw material attributes and tablet process parameters and relates these to final tablet attributes. Prior to a manufacturing batch, the resulting models are used in an optimization framework to find optimal process conditions which can satisfy desired final tablet attributes while taking into account the attributes of specific raw material lots to be used in the batch. The obtained process parameter space can be considered a Quality by Design (QbD) design space as defined by the ICH-Q8 guidance [1] . To implement the FF control, an in-house process simulator is presented. The effectiveness of the methodologies is illustrated through a common industrial tablet manufacturing case study.
METHODS

Data structure
The generalized data structure available in a general tablet development process is shown in Fig.1 data base matrix containing attributes on all the available raw materials, including both lots used and not used in the past tablet batch manufacturing operations for a particular product. The X matrix is a subset of DB X . Some attribute data in the DB X matrix can be obtained from suppliers of the raw materials (Certificates of Analysis). Additional raw material characterization may be required to develop more robust relationships. Fig.1 . Generalized data structure available in tablet development
Simultaneous PLS modeling using raw material attributes and process parameters on final tablet attributes
The key question in modeling is how to build the model relating raw material attributes ( X ) and process parameters ( Z ) to the final tablet attributes ( Y ). The PLS model [4] which simultaneously takes into account two degrees of freedom such as raw material attributes ( X ) and process parameters ( Z ) [10] [11] is generically expressed as:
where  is the model error including measurement error.
If one wants to consider the effect of formulation composition ( R ) as well as raw material attributes ( X ) and process parameters ( Z ), mixture-property PLS models [10, 11] can simultaneously take into account the three degrees of freedom for a general chemical mixture product design and can be used. There are several advantages to the PLS models shown in Eq.1: (1) It can provide information on which of the raw material attributes and process parameters have more relative impact on final tablet attributes; (2) With a new raw material lot/grade and process parameters which have never been used in the past, the PLS models can estimate the final tablet attributes in-silico prior to any manufacturing or experimentation experience; (3) the built PLS models can be suitably applied in an optimization framework to find the best process parameters which can achieve desired tablet attributes subject to incoming raw material lot variations.
Process optimization strategy using PLS models
In this section, it is assumed that the required data are available and forces the solution to lie in the space of the PLS model [8, 9] . The objective function is a weighted measure of the estimation error between the desired tablet attributes and the estimated tablet attributes through the PLS model. Here, only one term is used in the objective function, but some other cost functions such as manufacturing process utility cost can be easily added, if needed. Solutions to these NLP (Nonlinear Programming) problems were obtained using the sequential quadratic programming (SQP) approach [7, 13] . MATLAB was used for the execution.
INDUSTRIAL EXAMPLE
The effectiveness of the above methodologies is illustrated through an industrial tablet manufacturing case study. These immediate release tablets are comprised of an Active Pharmaceutical Ingredient (API) and four excipients (i.e., Microcrystalline Cellulose (MCC), Fast Flo Lactose (FFL), Sodium Starch Glycolate (SSG) and Magnesium Stearate (MgSt)). The attributes of these pure raw materials modeled in the study were particle size distribution, water content, specific surface area and acid content. Only the attributes of MCC, FFL and MgSt have been taken into account in the final modeling and optimization stages, because they were shown to affect tablet attributes in a preliminary study undertaken to determine an appropriate set of raw material attributes for the final models (variable selection). The tablet manufacturing process was a common dry granulation process consisting of blending, roller compaction, milling and tableting unit operations. The process parameters evaluated in this study were roll force, roll speed, screen aperture size, blender load during lubrication, tablet compaction force and speed. The final tablet attributes used for this example were tablet hardness (strength) profile with compaction force, in-vitro tablet dissolution and tablet disintegration time. The data matrix size and structure used in this study are described in Fig.2 ). The total number of X and Y variables on the final tablet attributes is shown in Table I . 
X
and Y is generally much larger than that of the number of drug product manufacturing batches. This often occurs because the number of larger scale batches tends to be small due to operation cost and the total number of variables (e.g., raw material lots and attributes, process parameters, final tablet attributes) tends to be relatively large due to the complex nature of the drug product process. For such cases, common statistical tools such as Ordinary Least Squares (OLS) will rarely work. The number of samples has to be (at least) two or three times larger than that of the number of columns/variables for successful OLS regression (even with independent X variables), else, the OLS model would easily result in overfitting. PLS has the potential to overcome this problem by reducing the original dimensions into a much lower dimensionality subspace (i.e. PLS components), and the PLS components may be small enough relative to the number of manufacturing batches. If so, the resulting PLS model would provide robust estimates.
RESULTS AND DISCUSSION
Result of PLS model ability
The ability of the PLS models to account for each tablet attribute is shown in Table I . The R2 shows the fraction of the cumulative sum of squares of the response variables explained by the fitted model, and the Q2 shows the cumulative sum of squares of prediction obtained from cross validation. The number of PLS components for each 8th IFAC Symposium on Advanced Control of Chemical Processes Furama Riverfront, Singapore, July 10-13, 2012 model was selected so as to maximize the Q2 value and avoid the overfitting problem. Both R2 and Q2 are generally important indicators for large samples of datasets. As can be seen in Table I , the built PLS models provide good estimates of all the Y variables such as tablet hardness profile, dissolution profile and disintegration time (R2 value of all the Y variables is more than 80%). The Q2 value of the tablet strength results in being slightly lower while that of disintegration time and dissolution profile is sufficiently large. Notice that the number of PLS components used is much smaller than that of original dimensions of all X and Y matrices. This indicates that the original variables were highly correlated to each other. Moreover, the number of PLS components is small relative to the number of manufacturing batches, while the total number of original variable dimensions of all X and Y was much larger than the number of manufacturing batches. Therefore, the dimension reduction of PLS modeling was a significant advantage for this modeling study. As mentioned above, the data structure and process nature of this study is a very common case in general pharmaceutical tablet development. The use of PLS modeling may not be just an option but an imperative for a QbD study which has to simultaneously take into account the relationship of many variables such as the raw material attributes, process parameters and final tablet attributes with a relatively small number of drug product batches. The PLS model can provide the information about which raw material attributes and process parameters have more impact on final tablet attributes. In order to recognize the overall key parameters, the results of the top-10 VIP (Variable Influence of Projection) plot on the tablet hardness profile, dissolution profile and disintegration time are shown in Fig.3(a) , Fig.3(b) and Fig.3(C) , respectively. The process parameters and raw material attributes having a VIP>1.0 significantly contribute to the final tablet attributes [12] . There are two key results: (a) in general the process parameters contribute a larger effect on the final tablet attributes, compared to the raw material attributes; (b) the key process parameters and raw material attributes are different depending on the final attribute (i.e., the tablet hardness profile, dissolution profile and disintegration time). The VIP rankings on each final tablet attribute matched experimental observations.
Effect of raw material lot-to-lot variability on the tablet hardness profile
Based on the built PLS model, the effect of all the possible variability from excipient material lots on the final tablet attributes has been investigated using the excipient material lot database ( ). For an efficient simulation, only the excipient lots that maximize variance in each excipient space (e.g. PC1 vs. PC2 by Principal Component Analysis) were chosen. During the simulation, a nominal (fixed) process condition was used. In this simulation, the tablet hardness profile was primarily investigated as it has the biggest contribution to the performance of this drug product. The result of this lot to lot variability on the tablet hardness profile is shown in Fig.4 . The wider region (colored yellow) and the smaller region (colored green) correspond to the total variability of all the possible excipient material lots and the target region, respectively. Most batches resulted in being within the target region, but some batches were outside the target region. Therefore, a process optimization approach which takes into account the excipient lot to lot variability could provide additional process understanding for this case, could help to de-risk the overall manufacturing operations for this product and produce a more consistent drug product. 
Result of process optimization
The effect of all the possible excipient lot to lot variability on the final tablet attributes (colored by yellow in Fig.4) should be taken into account in the process optimization design. The range is first divided into three case regions (Case1, Case2, Case3) which corresponds to lower, middle and higher tablet hardness profile, as shown in Fig.5 , in order to clearly demonstrate the change (transition) of optimal process parameters and final tablet attributes subject to the excipient lot variability. The upper region of Case3 and the lower region of Case1 shown in Fig.5 fall outside the target region, as shown in Fig.4 , and are of particular interest. The excipient lot combinations corresponding to the above three cases were found through the simulation in the previous section, and were set as the constraints ( current x in Eq.7) in the optimization framework. The centered line in the target region shown in Fig.4 is set as the target tablet hardness profile des y in Eq.7. The other constraints such as process parameter ranges, dissolution profile and disintegration time were suitably set. The result of the process parameter (regions) optimization subject to the excipient lot combinations (corresponding to the Case1, Case2 and Case3) is shown in Fig.6 . Only the results of three key process parameters Z2, Z3 and Z6 are shown here, while the result of six process parameters is simultaneously obtained. The range of process parameter constraints is shown by the green line. Notice that the optimal process parameter region clearly changes depending on the excipient lot combination cases (Case1, Case2, Case3). This indicates and confirms that the process parameters can be changed to compensate for the effect of the excipient lot changes. The reason why the optimal process parameter regions (Case1, Case2, Case3) discretely change is because they are determined so as to minimize the objective function in Eq.7 (i.e. the error between the desired tablet hardness profile and the estimate) at each excipient combination case. If defining another objective function in the optimization framework (i.e. another criteria), another optimal process parameter region will be obtained. The result of tablet hardness profile, dissolution profile and disintegration time using these optimal process parameters is simulated and shown in Fig.7 . All the desired final tablet attributes are well satisfied for all the possible excipient lot combinations (Case1, Case2, Case3), by selecting the optimal process parameters. This means that the process optimization has compensated for the effect of raw material lot variability and even excipient lots that fell outside of the target region with a fixed process produced acceptable tablets. This is a tangible benefit provided by the proposed process optimization strategy. There is still some room on the constraints of the desired dissolution profile and disintegration time, while there is not much on the tablet hardness profile (especially Case3). Such information enhanced the process understanding of design space during drug development. (Fig.6 and Fig.7 ) can be considered as the suitable design space for a QbD study. The optimum process parameter space to achieve the desired final attributes may change with the variance in the raw material attributes. These studies provide a good "multidimensional and interactive relationship of raw material attributes and process parameters on final tablet attributes", which is defined by the ICH-Q8 guidance [1] . The above methodologies using latent variable modeling and optimization technology can play a key role in presenting a suitable design space for a QbD study.
IN-HOUSE PROCESS SIMULATOR
To aid operators in the selection of process parameters per excipient characteristics, an in-house process simulator for the proposed process optimization strategy has been developed using MATLAB. The simulator calculates the best process parameters within the selected constraints 8th IFAC Symposium on Advanced Control of Chemical Processes Furama Riverfront, Singapore, July 10-13, 2012 (e.g., incoming raw material lots and process parameter ranges) to ensure desired final tablet attributes are obtained for every batch, prior to manufacturing a batch. The simulator serves as a decision support system for the operators. The screen shot of the process simulator is shown in Fig.8 . The column portions colored in blue and yellow show the input and output information, respectively. As input information, the incoming excipient lot (upperleft side of the screen) and the process parameter range constraints (lower-left side of the screen) can be selected. After pressing the "optimization" button, the optimal process parameters are provided in the yellow colored column (lower-left side of the screen), and the estimated final tablet attributes (tablet hardness profile, dissolution profile and disintegration time) using the optimal process parameters are provided (right side of the screen). 
CONCLUSION
A Feed-Forward process control strategy which can compensate for the effect of raw material lot to lot variability to achieve the desired final tablet attributes has been successfully applied to a common industrial manufacturing (pharmaceutical tablet) process. The PLS model simultaneously takes into account raw material attributes and process parameters and provided very good estimates on the final tablet attributes (tablet hardness profile, dissolution profile, disintegration time). The dimensionality reduction capability of PLS modeling was a significant advantage in this study, as the total number of original dimensions of all X and Y is much larger relative to the total number of batches available. Many other common industrial cases would have a similar situation. The constructed PLS model provided useful information about which raw material attributes and process parameters have more impact on the final tablet attributes. Based on the PLS model, the total variability of raw material lots on the final tablet attributes was investigated using the raw material database, and then the optimal process parameter spaces (taking into account the total raw material variability to ensure desired final tablet attributes) was found. These results can be considered as a design space for a Quality by Design (QbD) study. This approach is able to demonstrate a multidimensional and interactive relationship of raw material attributes and process parameters on final tablet attributes, which is defined by the ICH-Q8 guidance [1] .
